IGI Laboratories Lowered to Sell at Thomson Reuters/Verus (IG)
IGI Laboratories (NYSE:IG) was downgraded by investment analysts at Thomson Reuters/Verus from a “hold” rating to a “sell” rating in a note issued to investors on Monday, AnalystRatings.NET reports.
Separately, analysts at Roth Capital initiated coverage on shares of IGI Laboratories in a research note to investors on Wednesday, August 7th. They set a “buy” rating and a $3.50 price target on the stock.
IGI Laboratories (NYSE:IG) traded down 3.41% on Monday, hitting $1.98. 22,900 shares of the company’s stock traded hands. IGI Laboratories has a one year low of $0.98 and a one year high of $2.28. The stock has a 50-day moving average of $1.93 and a 200-day moving average of $1.68. The company’s market cap is $85.6 million.
IGI Laboratories, Inc (NYSE:IG) develops, manufactures, fills and packs topical semi-solid and liquid products for cosmetic, cosmeceutical and pharmaceutical customers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.